Sumitomo treats first patient in Phase I/IIa trial of DSP-3077

The study will assess the tolerability and safety of two dose levels of DSP-3077 delivered via a single subretinal injection.

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

MARLBOROUGH, Mass.-- (BUSINESS WIRE)--Aug 12, 2026-- ...